BACKGROUND: Maternal pregestational diabetes is a well-known risk factor for congenital anomalies. This study analyses the spectrum of congenital anomalies associated with maternal diabetes using data from a large European database for the population-based surveillance of congenital anomalies. METHODS: Data from 18 population-based EUROCAT registries of congenital anomalies in 1990-2005. All malformed cases occurring to mothers with pregestational diabetes (diabetes cases) were compared to all malformed cases in the same registry areas to mothers without diabetes (non-diabetes cases). RESULTS: There were 669 diabetes cases and 92,976 non diabetes cases. Odds ratios in diabetes pregnancies relative to non-diabetes pregnancies comparing each EUROCAT subgroup to all other non-chromosomal anomalies combined showed significantly increased odds ratios for neural tube defects (anencephaly and encephalocele, but not spina bifida) and several subgroups of congenital heart defects. Other subgroups with significantly increased odds ratios were anotia, omphalocele and bilateral renal agenesis. Frequency of hip dislocation was significantly lower among diabetes (odds ratio 0.15, 95% CI 0.05-0.39) than non-diabetes cases. Multiple congenital anomalies were present in 13.6 % of diabetes cases and 6.1 % of non-diabetes cases. The odds ratio for caudal regression sequence was very high (26.40,), but only 17% of all caudal regression cases resulted from a pregnancy with pregestational diabetes. CONCLUSIONS: The increased risk of congenital anomalies in pregnancies with pregestational diabetes is related to specific non-chromosomal congenital anomalies and multiple congenital anomalies and not a general increased risk. Birth Defects Research (Part A) 94:134-140, 2012. Ó
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INTRODUCTION
Maternal diabetes is a well-known risk factor for congenital anomaly (CA). It has also been known for many years that good metabolic control in the preconceptional period decreases the risk of CA (Moelsted-Pedersen et al., 1964; Greene, 1999; Kitzmiller et al., 2010) . Maternal hyperglycemia is teratogenic, imposing the same risk of CA to pregnant women with type 1 or type 2 diabetes (Schwartz and Teramo, 2000; Farrel et al., 2002) . Furthermore, the relationship between maternal hyperglycemia in early pregnancy and the frequency of CA seems to be linear without any threshold level (Greene, 1999; Schwartz and Teramo, 2000) . However, several theories have been raised in the literature concerning the primary etiologic factor without a clear consensus (Zabiki et al., 2010) .
It is estimated in publications from Europe and the United States that 0.3% of all pregnant women have pregestational diabetes (Sheffield et al., 2002; Penney et al., 2003; Savona-Ventura et al., 2003) with the majority of the women having type 1 diabetes. There has been a significant increase in type 1 diabetes in children and young adults born after the mid 1980s (Gale, 2002; Svensson et al., 2002) . Therefore, it is expected that there will be an increase in the number of pregnant women with type 1 diabetes in the future. There is also a global increase in type 2 diabetes, thus the number of pregnant women with type 2 diabetes is also expected to increase.
In recent studies of pregnancies with pregestational diabetes, the risk of CA has been estimated to be between 5.0 and 11.9% (Casson et al., 1997 , Sheffield et al., 2002 Penney et al., 2003; Evers et al., 2004 , Jensen et al., 2004 compared to 2 to 3% in the background population (Boyd et al., 2011) . The types of CAs in diabetes pregnancies differ from those in nondiabetic pregnancies, with a higher proportion of anomalies affecting the central nervous system including neural tube defects (NTDs), the heart, and the kidneys (Kucera, 1971; Becerra et al., 1990; Schwartz and Teramo, 2000, Sheffield et al., 2002; Macintosh et al., 2006; Correa et al., 2008) . The rare malformation caudal regression sequence has a strong association with maternal diabetes (Becerra et al., 1990; Greene, 1999; Schwartz and Teramo, 2000) . Sirenomelia has been described as being the more severe form of caudal regression sequence, although there are different opinions in the literature (Das et al., 2002; Duesterhoeft et al., 2007; Bruce et al., 2009) . A recent multicenter-study found that maternal diabetes was present in 5% of pregnancies with sirenomelia (Orioli et al., 2011) . However, published data on the specific types of CA in diabetes pregnancies are mainly from small studies with only a small number of malformed cases.
The aim of this study is to investigate the spectrum of CA associated with pregestational maternal diabetes using data from a large European database for the population-based surveillance of congenital anomalies.
MATERIALS AND METHODS
The EUROCAT registries are population based and survey geographically defined populations. The methods of case ascertainment within the EUROCAT registries are described elsewhere (www.eurocat-network.eu). The registries are all based on multiple sources of information such as hospital records, birth and death certificates, and post mortem examinations, and include information about live births (LB), fetal deaths (FD) with gestational age (GA) greater than 20 weeks, and terminations of pregnancy after prenatal diagnosis of a fetal anomaly (TOPFA). All major structural malformations, monogenic syndromes and chromosomal anomalies are included in the database. Minor anomalies are excluded. Data quality indicators for all registries have been published .
The study included all cases of mothers with pregestational diabetes and born in the 18 EUROCAT registry areas during 1990 to 2005. The 18 registries are: Norway, Funen County (Denmark), Mainz and Saxony-Anhalt (Germany), Northern Netherlands, Hainaut-Namur and Antwerp (Belgium), Wales, Northern Region (United Kingdom), Cork and Kerry (Ireland),Vaud (Switzerland), Strasbourg and Iles de Reunion (France), Tuscany and Emilia-Romagna (Italy), Basque Country (Spain), South Portugal, and Malta. Some registries did not cover the whole time period. The total number of births covered during the study period was 3,729,230.
The central EUROCAT database was searched for all possible International Classification of Diseases (ICD) version 9 and 10 codes and written text for diabetes in the variables ''maternal illness before pregnancy'' and ''maternal illness during pregnancy'', codes and text for ''infant of diabetic mother'' and insulin use recorded in the variable ''drug use in pregnancy'' to find cases for which maternal diabetes had been recorded. The cases were then reviewed by the local registries to exclude those with gestational diabetes. Controls were all malformed babies or fetuses in the same registries without pregestational or known gestational diabetes (nondiabetic cases).
Data on diabetes and nondiabetic cases included type of birth (LB, FD, or TOPFA), time of diagnosis, GA, birth weight, one week survival, maternal age, maternal disease before pregnancy, maternal disease during pregnancy and codes for drug use. Up to eight anomalies and a syndrome code (if present) per baby or fetus are coded according to ICD9 or ICD10 with British Pediatric Association (BPA) extensions, and the cases are allocated to subgroups of anomalies based on the ICD BPA codes. One baby or fetus may be allocated to more than one subgroup; for example, spina bifida was included in the following subgroups: all anomalies, nervous system, NTD, and spina bifida.
We did a complete evaluation of all congenital anomalies registered for all diabetes cases. These cases were classified into only one of the following groups: chromosomal cases, monogenic syndromes, isolated NTD, isolated congenital heart defects, isolated renal anomalies, other isolated anomalies, and multiple anomalies, using the EUROCAT computer algorithm for multiple anomalies followed by manual review of all potential multiple cases . For the purposes of comparison of anomaly group distribution, a random sample of twice as many nondiabetic cases (n 5 1338) were classified and reviewed in the same way.
The VATER/VACTERL association (Botto et al., 1997) was identified according to the specific ICD/BPA code (759895 and Q8726) and for most registries also by written text. The VATER/VACTERL diagnosis was given locally by clinicians or registries, not centrally on the basis of the presence of three or more of the component anomaly codes. For the two anomalies caudal regression sequence and sirenomelia, the nondiabetic cases were searched for in the dataset based only on written text description, because coding may be nonspecific and heterogeneous. Analysis of caudal regression and sirenomelia was restricted to registries with text information describing the congenital anomalies for all cases.
Statistics
Statistical analysis was conducted using SPSS Statistics version 17.0 (SPSS, Chicago, IL) and STATA version 9.0 (StataCorp LP, College Station, TX). The odds of having each specific congenital anomaly subgroup among diabetes cases was compared with the odds of having that specific congenital anomaly subgroup among nondiabetic cases, to give crude odds ratios (ORs). A logistic regression model was used to calculate ORs for 86 EUROCAT nonindependent nonchromosomal anomaly subgroups adjusting for registry, maternal age, and year of birth (entered as a linear term). Because of the many subgroups and the problem of spuriously statistically significant results by multiple testing, only nonchromosomal anomaly subgroups with significantly increased risk at p < 0.01 level or with minimum five diabetes cases in the subgroup cases are presented in the Results. A random sample of nondiabetic cases were selected using the built-in SPSS select if function, which randomly selected 1338 nondiabetic cases of the total 92,976 nondiabetic cases.
RESULTS
The study identified 669 cases notified to the EUROCAT Central database to mothers with pregestational diabetes. The number of nondiabetic congenital anomaly cases in the same registries and the same time period was 92,976. The percentage of pregestational diabetes among all babies or fetuses with a congenital anomaly was 0.72%.
Descriptive Parameters
There was no difference in type of birth for diabetes cases and nondiabetic cases with 573 live births (86%) and 79,349 (85%), respectively. Eleven percent of diabetes cases resulted in a TOPFA (76 cases) compared with 13% of nondiabetic cases (11, 936) . Fetal deaths occurred in 20 diabetes cases (3%) and 1691 nondiabetic cases (2%). Sixteen percent of diabetes live births were diagnosed prenatally, compared with 15% of the nondiabetic liveborn cases.
Maternal age at delivery was higher for diabetes cases compared with nondiabetic cases and the background populations, with 27% of diabetic mothers being 35 years or older at the time of birth compared with 19% of the nondiabetic mothers and 17% in the background populations. Mean maternal age for diabetes cases was 30.7 years (6SD 5.8) and for nondiabetic cases was 29.5 years (6SD 5.7; p < 0.001).
Liveborn infants with congenital anomalies from diabetes pregnancies were heavier (p < 0.001) and born at a lower GA (p < 0.001) than nondiabetic liveborn cases. For live born diabetes cases, 8% were born before 32 weeks' gestation, 35% at 32 to 36 weeks, 47% at 37 to 39 weeks, and 7% at 40 weeks or greater. For all nondiabetic cases, the respective percentages were 3, 12, 42, and 39%. Median birth weight for GA was higher for the malformed diabetes cases than for the malformed nondiabetic cases for all liveborn cases born with GA less than 42 weeks ( Fig. 1) .
Among the diabetes cases, there were 344 males (51.4%), 317 females (47.4%), and three cases with indeterminate sex (0.4%). Sex was unknown for four TOPFA cases and one fetal death (0.7%). Among nondiabetic cases, 54.7% were males, 43.2% were females, and 0.3% were indeterminate, and 1.8% cases were unknown. The ratio of males to females for diabetes cases was 1.09 (95% confidence interval [CI], 0.92-1.25); compared with the ratio of males to females for nondiabetic cases at 1.27 (95% CI, 1.25-1.28) (100) All cases counted only once.
Type of Anomaly
Among diabetes cases there were 38 chromosomal (5.7%) and 631 nonchromosomal cases (94.3%). For all nondiabetic cases, there were 11,673 chromosomal (12.5%) and 81,303 (87.5%) nonchromosomal cases. The overall OR for nonchromosomal versus chromosomal cases was 2.38 (95% CI, 1.72-3.31; p < 0.001).
Cases were classified by type of anomaly using the computer algorithm and manual review (Table 1) . Isolated congenital heart defects were present in 38.3% and multiple anomalies in 13.6% of the diabetes cases compared to 24.9% isolated congenital heart defects and 6.1% multiple anomalies in the random sample of the nondiabetic cases (n 5 1338) Table 2 shows the ORs for each EUROCAT subgroup compared with all other nonchromosomal anomalies combined. A subgroup is shown if there are at least five diabetes cases or if the difference is significant (p < 0.01). Adjusting for maternal age, time period, and registry made no difference in the overall findings. Significantly increased ORs were found for: neural tube defects (anencephaly and encephalocele, but not spina bifida). For a number of congenital heart defects, the risk was increased. However, the ORs for tetralogy of Fallot and single ventricle were raised, but this did not reach statistical significance, whereas the ORs for pulmonary valve stenosis and hypoplastic left heart were not raised at all. Other subgroups with significantly raised ORs were anotia, omphalocele, and bilateral renal agenesis.
Subgroups less likely to be associated with diabetes included limb defects in general, and hip dislocation (OR, 0.15; 95% CI, 0.05-0.39) and syndactyly in particular (OR, 0.23; 95% CI, 0.09-0.62). Both cleft lip (with or without cleft palate) and isolated cleft palate are less likely to be associated with diabetes, but this was only statistically significant for cleft lip with or without palate (OR, 0.52; 95% CI, 0.31-0.88).
There were three cases of VATER/VACTERL associated with maternal diabetes (OR, 3.37; 95% CI, 1.07-10.65; Table 3 ). The component anomaly anal atresia was slightly but not significantly increased (OR, 1.32; 95% CI, 0.72-2.40), but the component anomalies esophageal atresia (OR, 1.04; 95% CI, 0.49-2.19) and limb reduction defect (OR, 1.01; 95% CI, 0.61-1.66) showed no evidence of association with diabetes.
Among registries with text descriptions of all malformations, we found four diabetes cases with caudal regression sequence and one diabetes case with sirenomelia. There were 21 nondiabetic cases diagnosed with caudal regression sequence and 15 nondiabetic cases with sirenomelia. The difference in frequency of caudal regression sequence between diabetes cases and nondiabetic cases was highly significant (OR, 26.40; 95% CI, ; p < 0.0001). However, only 17% of all babies or fetuses with caudal regression sequence and 6.3% of those with sirenomelia were from a pregnancy with pregestational diabetes.
DISCUSSION
This study has to our knowledge presented the largest case series of malformed babies or fetuses of mothers with pregestational diabetes. We cannot directly assess the overall relative risk of CA associated with maternal diabetes, because we do not have a comparison group of nonmalformed babies. However, our data suggest that the overall risk of CA associated with diabetes is more than doubled; 0.7% of babies with CA were associated with maternal diabetes, which is more than twofold the population prevalence of maternal diabetes of 0.3% usually estimated (Sheffield et al., 2002; Penney et al., 2003; Savona-Ventura et al., 2003) . This finding is consistent also with the OR of 2.38 for nonchromosomal anomalies compared with chromosomal anomalies, assuming that diabetes is not associated with chromosomal anomalies and accounting for the slightly higher maternal age in diabetes cases. There is good evidence that glycemic control reduces the risk of congenital anomaly (Jensen et al., 2004; Kitzmiller et al., 2010) . Our data represent the average situation across 18 registry areas in Europe during 1990 to 2005. As a result of glycemic control possibly improving in populations, the overall level of risk of congenital anomalies associated with diabetes should decrease.
The risk found in our study is consistent with other studies that compare anomaly rate in cohorts of diabetes pregnancies to the background population (Casson et al., 1997; Penney et al., 2003; Evers et al., 2004; Jensen et al., 2004) . In some of these studies, the documentation of CA in the background population was not entirely comparable to the diabetes population, leaving the possibility that risks were inflated by relatively more assiduous documentation of CA in diabetic pregnancy outcomes. Only one study from Hungary, where more than half the population took periconceptional folic acid, found a lower increase in risk (OR, 1.5; 95% CI 1.1 -2.0) for major CA in type 1 diabetes pregnancies compared with nondiabetic pregnancies (Banhidy et al., 2010) .
Our study did not find statistically significant differences in the likelihood of prenatal diagnosis or vital status at birth between diabetic and nondiabetic cases. The malformed live-born infants from pregestational diabetes pregnancies had higher birth weight and lower GA compared with the nondiabetic malformed cases. The lower GA is well explained by the induction of birth at GA 38 weeks for many pregnancies with pregestational diabetes because of the risk of macrosomia. Our data do not support a male predominance in infants with CA from diabetes pregnancies as published from the Netherlands (Evers et al., 2009) .
Our finding that diabetes is associated with anencephalus and encephalocele, but not spina bifida, requires further investigation. Most other diabetes studies have too few cases to classify NTDs into subgroups. Correa et al. (2008) found a significant risk for anencephalus, but not spina bifida or encephalocele, but this was based on only three to four diabetes-exposed cases of each of these anomalies. It is well known that folic acid taken during the periconceptional period reduces the risk of NTDs. Women with pregestational diabetes are advised to plan their pregnancies and to optimize their diabetic control before pregnancy. At this stage, women with diabetes should also be encouraged to take folic acid. The advised dose is 5 mg, as recommended for women with a previous NTD pregnancy (Wilson, 2003; Kitzmiller et al., 2010) , although there is not full agreement (Kitzmiller et al., 2010) . Evidence suggests that folic acid is more protective against spina bifida than anencephaly and encephalocele (de Wals et al., 2007) , and further research is needed on the complex relationships among diabetes, folic acid, and type of NTD.
Our study showed that congenital heart defects were 2.2-fold more frequent in diabetes pregnancies relative to other CAs, and congenital heart defects accounted for the vast majority of excess risk of CA among diabetes exposed pregnancies. ORs were higher for atrial septal defect (ASD; 2.27; 95% CI, 1.83-2.81) than (ventricular septal defect (VSD); OR, 1.47; 95% CI, 1.21-1.78). Congenital heart defects requiring surgery with ORs as high as those for ASD were common arterial truncus, common atrioventricular canal, and single ventricle, although the last of these did not reach statistical significance. There was no evidence of an association with diabetes for pulmonary valve stenosis and hypoplastic left hearts compared with other CAs. The increased risk of ASD, VSD, and transposition of great arteries has been described by Correa et al. (2008) . ASD and ventricular septal defect (VSD) may in part be increased because diabetes cases are more likely to have a neonatal admission and thus more likely to have an echocardiography performed.
The increased risk of anotia or microtia (Correa et al., 2008) and bilateral renal agenesis (Sharpe et al., 2005; Correa et al., 2008; Banhidy et al., 2010) has been found by others previously. We have found only one published study with specified data on omphalocele (Correa et al., 2008) , and the risk was significant for omphalocele only as part of multiple defects (three exposed cases), not as isolated omphalocele (one exposed case). Our study included 13 diabetes cases with nonchromosomal omphalocele, resulting in an OR of 2.28 (95% CI, 1.31-3.97) compared with nondiabetic cases. We could not confirm the previously reported increased risks of hydrocephalus (Correa et al., 2008) , cleft lip (Correa et al., 2008) , anal atresia (Frias et al., 2007; Correa et al., 2008) , limb reduction defects (Sharpe et al., 2005; Correa et al., 2008) , and hypospadia (Sharpe et al., 2005) .
Based on case reports, VATER/VACTERL association has been suggested to be related to maternal diabetes (Castori et al., 2008) . We also found a significantly increased OR for VATER/VACTERL association, though based on only three cases, but for the individual CA involved in VATER/VACTERL association (esophageal atresia, anal atresia, and limb reduction defects) we could not find a significantly increased risk. We found that 13.6% of diabetes cases had multiple CAs compared with 6.1% among nondiabetic pregnancies Our data suggest that diabetes is protective against hip dislocation. We found that infants from diabetes pregnancies have a lower GA and a higher birth weight for GA than nondiabetic cases. It is possible that it is the lower GA of the diabetes births that is protective against hip dislocation. A previous study from Australia found that both high birth weight and high GA are independent risk factors for hip dislocation (Chan et al., 1997) . However, some caution should be exercised in the interpretation of our results, because the diagnostic criteria for hip dislocation vary and there was not a consistent definition across Europe.
The rare malformation caudal regression sequence has been described in the literature to have a strong association with maternal diabetes (Greene, 1999; Schwartz and Teramo, 2000; Becerra et al., 1990) . In our study, we found a highly significant increased risk of caudal regression in the diabetes pregnancies. However, only 17% were from pregnancies with pregestational diabetes, although there may have been some diabetes cases misclassified as nondiabetic cases. Our data suggest that, whereas diabetes is a strong risk factor for caudal regression, etiologies other than diabetes are important, such as mutations in the VANGL1 gene (Kibar et al., 2007) .
The strength of our study is the high number of diabetes cases and the standardized and specific classification of all cases throughout the 18 registry areas. Our proportion of diabetes exposure among congenital anomaly cases of 0.7% was within the expected range. This would not, however, bias ORs for specific CAs compared with all other CAs. An additional limitation of our study is that we lacked data on nonmalformed controls in our dataset, which meant that we could not estimate the risk of CA as a whole, or of subgroups relative to the nondiabetic population, but could only analyze the specificity of the association of certain malformations with diabetes. In such a proportional analysis, when some anomalies are significantly increased, others must be decreased; therefore, slightly decreased ORs do not necessarily reflect a protective effect of diabetes. Because we tested many subgroups, some statistically significant findings will also arise by chance and may be considered ''signals'' for further research when there is no supporting literature. It is also a limitation that we do not have information on preconceptional use of folic acid in our study population.
For some of our cases, we did not know whether the woman had type 1 or type 2 diabetes. In this European population with births during 1990 to 2005, it is likely that most of the pregnancies had type 1 diabetes (Macintosh et al., 2006; Whitworth et al., 2011) . For the nondiabetic control group, we deleted all cases with known gestational diabetes. We recommend that future studies on diabetes and congenital anomalies consider the distinction between type 1 and type 2 diabetes, and also consider whether glycemic control reduces the risk of all or selected diabetes-associated anomalies.
This study confirmed that the risk of major nonchromosomal CA is at least twice as high in pregnancies with pregestational diabetes compared with nondiabetic pregnancies. The risk is not a general increased risk, but it is related to specific nonchromosomal anomalies and multiple congenital anomalies. Although caudal regression sequence is strongly related to pregestational diabetes, other factors are important in the etiology of caudal regression.
